The meeting of the American Society of Oncology focused on optimizing immunotherapy and other advanced treatments for ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm ...

EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets a tumour-specific N-glycosylated epitope on both CEACAM5 and CEACAM6.

a B7-H4 targeted antibody-drug conjugate (ADC), will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The Phase 1 study is evaluating LNCB74 as monotherapy ...

A conjugate vaccine is a substance that is composed of a polysaccharide antigen fused (conjugated) to a carrier molecule. This enhances the stability and the effectiveness of the vaccine.

Elon Musk’s prominent role in President Donald Trump’s White House appears to be fading, but the tech billionaire’s brainchild — the budget-slashing Department of Government Efficiency ...

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID. Please note: If you switch to a different device, you may be asked to login again with only ...

EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, tumour-specific N256-glycosylated epitope on CEACAM5 and CEACAM6. It is currently undergoing Phase 1 clinical trials for ...

- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W)- SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE ...

– 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W) – “EpCAM is a high potential and broadly expressed cancer ...